Bioxytran (BIXT) Revenue Growth (3y) (2013 - 2018)
Bioxytran (BIXT) Revenue Growth (3y) (2013 - 2018) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -25.02% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 42.02% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 59.40% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -37.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 76.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.80% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | -30.07% |
| Mar 31, 2018 | -40.27% |
| Dec 31, 2017 | 67.08% |
| Sep 30, 2017 | 39.22% |
| Jun 30, 2017 | 1.41% |
| Mar 31, 2017 | -67.08% |
| Dec 31, 2016 | -26.81% |
| Sep 30, 2016 | 22.00% |
| Jun 30, 2016 | -17.45% |
| Mar 31, 2016 | -34.91% |
| Dec 31, 2015 | -232.65% |
| Sep 30, 2015 | 123.48% |
| Jun 30, 2015 | -20.62% |
| Mar 31, 2015 | -22.34% |
| Dec 31, 2014 | -36.14% |
| Sep 30, 2014 | 46.50% |
| Jun 30, 2014 | 5.65% |
| Mar 31, 2014 | 197.28% |
| Dec 31, 2013 | 207.51% |
| Sep 30, 2013 | 214.52% |